Tamoxifen
Selective Estrogen Receptor Modulator (SERM) for Breast Cancer Treatment and Prevention
Quick Facts About Tamoxifen
Key Takeaways About Tamoxifen
- Proven breast cancer treatment: Tamoxifen reduces the risk of breast cancer recurrence by approximately 40–50% and breast cancer mortality by about one-third in ER-positive disease
- Long treatment duration: Standard therapy is 5–10 years; the ATLAS trial showed that 10 years of tamoxifen further reduces recurrence and death compared to 5 years
- CYP2D6 matters: Tamoxifen requires activation by the CYP2D6 enzyme; avoid strong CYP2D6 inhibitors (fluoxetine, paroxetine) as they significantly reduce efficacy
- Pregnancy is contraindicated: Tamoxifen can cause serious fetal harm – effective non-hormonal contraception is essential during treatment
- Monitor for serious risks: Increased risk of endometrial cancer, deep vein thrombosis, and pulmonary embolism – report unusual vaginal bleeding or leg swelling immediately
What Is Tamoxifen and What Is It Used For?
Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen from stimulating the growth of estrogen receptor-positive (ER+) breast cancer cells. It is used to treat ER+ breast cancer in both premenopausal and postmenopausal women, to reduce the risk of breast cancer in high-risk individuals, and to prevent recurrence after surgery.
Tamoxifen belongs to a class of medicines known as selective estrogen receptor modulators (SERMs). It works by competitively binding to estrogen receptors in breast tissue, where it acts as an anti-estrogen, blocking the stimulating effects of estrogen on cancer cell growth. Approximately 70–80% of all breast cancers are estrogen receptor-positive, making tamoxifen one of the most important drugs in breast cancer treatment.
In the treatment of early-stage ER+ breast cancer, tamoxifen is used as adjuvant endocrine therapy after surgery (with or without chemotherapy and radiotherapy). The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis demonstrated that 5 years of adjuvant tamoxifen reduces the annual breast cancer recurrence rate by approximately 40% and the annual mortality rate by approximately one-third, regardless of the use of chemotherapy, patient age, or menopausal status.
Tamoxifen is also used for the treatment of advanced (metastatic) ER+ breast cancer, where it can slow disease progression and improve quality of life. Additionally, it is approved for breast cancer risk reduction (chemoprevention) in women at high risk of developing the disease. The landmark NSABP P-1 trial demonstrated that tamoxifen reduced the incidence of invasive breast cancer by 49% in high-risk women.
It is important to understand that tamoxifen has tissue-specific effects. While it acts as an anti-estrogen in breast tissue (blocking estrogen-driven cancer growth), it has partial estrogenic (agonist) activity in other tissues. In bone, this estrogenic effect helps maintain bone mineral density, which can be beneficial especially in postmenopausal women. However, in the uterus, this estrogenic activity increases the risk of endometrial changes, including endometrial cancer.
Tamoxifen was first approved for medical use in 1977 and is included on the World Health Organization's List of Essential Medicines. It was originally developed by ICI Pharmaceuticals (now AstraZeneca) and has been called one of the most important drugs in the history of cancer treatment. Over four decades, it has saved hundreds of thousands of lives worldwide.
What Should You Know Before Taking Tamoxifen?
Before starting tamoxifen, inform your oncologist about your full medical history, especially any history of blood clots, stroke, endometrial problems, liver disease, or cataracts. Tamoxifen is strictly contraindicated during pregnancy. Patients who are CYP2D6 poor metabolizers may have reduced benefit from treatment.
Contraindications
You should not take tamoxifen if any of the following apply to you:
- Pregnancy or planned pregnancy – tamoxifen is a known teratogen and can cause serious birth defects, including craniofacial malformations and genital abnormalities. A pregnancy test should be performed before starting treatment
- Allergy to tamoxifen or any of the excipients in the tablet – symptoms may include skin rash, itching, swelling, or difficulty breathing
- Breastfeeding – it is not known whether tamoxifen passes into breast milk; breastfeeding should be discontinued during treatment
- Concurrent warfarin therapy for risk reduction – when tamoxifen is used for breast cancer risk reduction (not treatment), concurrent warfarin-type anticoagulant therapy is a relative contraindication due to increased bleeding risk
Tamoxifen must not be used during pregnancy. It can cause serious harm to the developing fetus. You must use effective non-hormonal contraception (such as barrier methods or a copper IUD) during tamoxifen treatment and for at least 2 months after stopping. Do not use hormonal contraceptives (the pill, patches, implants) as they may interfere with tamoxifen's action. If you become pregnant while taking tamoxifen, stop the medication immediately and contact your oncologist.
Warnings and Precautions
Talk to your oncologist before taking tamoxifen if you have or have had any of the following conditions:
- History of deep vein thrombosis (DVT) or pulmonary embolism (PE) – tamoxifen increases the risk of thromboembolic events by 2–3 fold. This risk is further elevated during periods of immobility (surgery, prolonged bed rest) and in combination with chemotherapy
- History of stroke or transient ischaemic attack (TIA) – tamoxifen may increase the risk of cerebrovascular events
- Uterine problems (fibroids, endometrial hyperplasia, abnormal vaginal bleeding) – tamoxifen's estrogenic effect on the uterus increases the risk of endometrial polyps, hyperplasia, and endometrial cancer. Regular gynaecological monitoring is recommended
- Liver disease – tamoxifen is extensively metabolised by the liver; impaired liver function may alter drug levels
- Cataracts or other eye problems – tamoxifen has been associated with cataracts, corneal changes, and retinopathy. Eye examinations may be recommended during treatment
- CYP2D6 poor metabolizer status – tamoxifen is a prodrug that requires conversion to active metabolites (particularly endoxifen) by the CYP2D6 enzyme. Patients who are genetically CYP2D6 poor metabolizers (approximately 7–10% of Caucasians) may have reduced benefit from tamoxifen therapy
Endometrial Cancer Risk
Tamoxifen increases the risk of endometrial cancer (cancer of the lining of the uterus) by approximately 2–7 times compared to the general population. This risk increases with duration of treatment and is primarily seen in postmenopausal women. Any unusual vaginal bleeding, bloody vaginal discharge, change in menstrual periods, or pelvic pain should be promptly reported to your doctor and investigated. Regular gynaecological examinations, including pelvic ultrasound, may be recommended during tamoxifen therapy.
CYP2D6 and Tamoxifen Activation
Tamoxifen is a prodrug – it must be converted in the body to its active metabolites, primarily endoxifen and 4-hydroxytamoxifen, to exert its anti-cancer effects. The enzyme CYP2D6 plays a critical role in this conversion. Patients who are CYP2D6 poor metabolizers (due to genetic variation) or who take strong CYP2D6 inhibitors (such as fluoxetine or paroxetine) may have significantly lower endoxifen levels, potentially reducing tamoxifen's effectiveness. Pharmacogenomic testing for CYP2D6 status may be considered before starting treatment.
How Does Tamoxifen Interact with Other Drugs?
Tamoxifen has clinically critical interactions with CYP2D6 inhibitors (especially fluoxetine and paroxetine), which can substantially reduce its anti-cancer efficacy. It also interacts with warfarin, aromatase inhibitors, and other medications. Always inform your oncologist about all medications, supplements, and herbal products you are taking.
Tamoxifen is metabolised primarily by CYP2D6 and CYP3A4 enzymes in the liver. Drugs that inhibit CYP2D6 are of particular concern because they can prevent the formation of endoxifen, tamoxifen's most potent active metabolite. This is not just a theoretical concern – clinical studies have demonstrated that concurrent use of strong CYP2D6 inhibitors is associated with higher breast cancer recurrence rates.
Major Interactions (Avoid Combination)
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Fluoxetine (Prozac) | SSRI antidepressant | Strong CYP2D6 inhibitor; reduces endoxifen levels by up to 64%, significantly decreasing tamoxifen efficacy | AVOID – switch to venlafaxine, citalopram, or escitalopram instead |
| Paroxetine (Paxil) | SSRI antidepressant | Potent CYP2D6 inhibitor; reduces endoxifen levels by up to 56%, linked to increased breast cancer mortality | AVOID – switch to a CYP2D6-safe antidepressant |
| Warfarin | Anticoagulant | Tamoxifen potentiates anticoagulant effect, significantly increasing INR and risk of serious bleeding | If unavoidable, monitor INR very closely and reduce warfarin dose as needed |
| Letrozole / Anastrozole | Aromatase inhibitors | Concurrent use reduces aromatase inhibitor plasma levels; tamoxifen may antagonise the effect of aromatase inhibitors | Do NOT use concurrently – use sequentially (one after the other) as directed by your oncologist |
Moderate Interactions (Use with Caution)
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Bupropion (Wellbutrin) | Antidepressant / smoking cessation | Moderate CYP2D6 inhibitor; may reduce endoxifen levels | Use with caution; consider alternative if possible |
| Duloxetine (Cymbalta) | SNRI antidepressant | Moderate CYP2D6 inhibitor; may reduce tamoxifen activation | Use with caution; venlafaxine is preferred if SNRI needed |
| Rifampicin | Antibiotic (TB treatment) | Strong CYP3A4 inducer; may reduce tamoxifen and endoxifen levels | Monitor treatment response; discuss alternatives with your doctor |
| Quinidine | Antiarrhythmic | Potent CYP2D6 inhibitor; reduces endoxifen formation | Avoid concurrent use if possible |
| Hormonal contraceptives | Oral contraceptives, patches, implants | Estrogen-containing products may counteract tamoxifen's anti-estrogenic action in breast tissue | Use non-hormonal contraception only (barrier methods, copper IUD) |
If you need an antidepressant while taking tamoxifen, the following options have minimal impact on CYP2D6 and are generally considered safe: venlafaxine (also helps with hot flashes), citalopram, escitalopram, and sertraline (at low doses). Always consult your oncologist before starting any new medication.
What Is the Correct Dosage of Tamoxifen?
The standard dose of tamoxifen for breast cancer treatment is 20 mg once daily, taken by mouth with or without food. Treatment typically continues for 5 to 10 years as directed by your oncologist. Do not change your dose or stop treatment without medical advice.
Always take tamoxifen exactly as your oncologist has prescribed. Tamoxifen tablets should be swallowed whole with a glass of water and can be taken at any time of day, with or without food. Taking it at the same time each day helps maintain consistent blood levels.
Adjuvant Breast Cancer Treatment
Early-Stage ER+ Breast Cancer (After Surgery)
Standard dose: 20 mg once daily
Duration: 5 to 10 years
The ATLAS trial (Lancet, 2013) demonstrated that continuing tamoxifen for 10 years further reduces recurrence and mortality compared to stopping at 5 years. Your oncologist will determine the optimal duration based on your individual risk profile, menopausal status, and tolerability. Some patients may be switched to an aromatase inhibitor after 2–5 years of tamoxifen if they become postmenopausal.
Advanced (Metastatic) Breast Cancer
Metastatic ER+ Breast Cancer
Standard dose: 20–40 mg daily
Doses above 20 mg should be divided (e.g., 20 mg in the morning and 20 mg in the evening). Treatment continues as long as the cancer responds and the drug is tolerated.
Breast Cancer Risk Reduction (Chemoprevention)
High-Risk Women
Standard dose: 20 mg once daily
Duration: 5 years
For women at high risk of developing breast cancer but who do not currently have the disease. The NSABP P-1 and IBIS-I trials showed a significant reduction in invasive breast cancer incidence with 5 years of tamoxifen. Low-dose tamoxifen (5 mg daily) is also being studied as an alternative with fewer side effects.
Missed Dose
If you forget to take a dose, simply skip it and take your next dose at the usual time. Do not take a double dose to make up for the missed one. If you miss doses frequently, consider setting a daily reminder or using a pill organiser. Consistent daily dosing is important for maintaining effective blood levels.
Overdose
Symptoms of tamoxifen overdose may include tremor, hyperreflexia (exaggerated reflexes), unsteadiness, dizziness, and seizures. In acute overdose, QT prolongation on the electrocardiogram has been reported. There is no specific antidote for tamoxifen overdose. Seek immediate medical attention if you suspect an overdose. Contact your local emergency services or poison control centre without delay.
What Are the Side Effects of Tamoxifen?
The most common side effect of tamoxifen is hot flashes (affecting up to 80% of patients). Other significant side effects include increased risk of venous thromboembolism (blood clots), endometrial changes, vaginal dryness or discharge, and cataracts. Most side effects are manageable, but some require monitoring.
Like all medicines, tamoxifen can cause side effects, although not everybody gets them. Many side effects are related to its anti-estrogenic properties and are similar to menopausal symptoms. Some side effects, such as the increased risk of endometrial cancer and blood clots, are serious and require regular medical monitoring.
- Sudden leg swelling, pain, or tenderness (possible deep vein thrombosis)
- Sudden shortness of breath, sharp chest pain, or coughing up blood (possible pulmonary embolism)
- Abnormal vaginal bleeding or bloody discharge (possible endometrial changes)
- Sudden severe headache, confusion, vision changes, or weakness on one side of the body (possible stroke)
- Severe allergic reaction: skin rash, swelling of face/lips/tongue, difficulty breathing
Very Common
May affect more than 1 in 10 people
- Hot flashes (up to 80% of patients)
- Vaginal discharge
- Menstrual irregularities (in premenopausal women)
- Fatigue
Common
May affect up to 1 in 10 people
- Nausea and gastrointestinal disturbance
- Vaginal dryness or itching
- Headache
- Fluid retention (oedema)
- Skin rash
- Joint pain (arthralgia) and muscle pain (myalgia)
- Leg cramps
- Mood changes, depression
- Weight changes
- Hair thinning
Uncommon
May affect up to 1 in 100 people
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)
- Endometrial polyps, hyperplasia, or cancer
- Uterine fibroids
- Cataracts and visual disturbances
- Elevated liver enzymes, fatty liver
- Triglyceride elevation
- Ovarian cysts (in premenopausal women)
Rare and Very Rare
May affect up to 1 in 1,000 people or fewer
- Stroke or cerebrovascular events
- Severe hepatotoxicity (liver damage), hepatitis, cholestasis
- Retinopathy, corneal changes
- Optic neuritis
- Interstitial pneumonitis
- Stevens-Johnson syndrome, erythema multiforme
- Angioedema
- Tumour flare (transient increase in bone pain at treatment initiation)
If you experience any side effects not listed here, or if any side effect becomes severe, contact your oncologist or pharmacist. Regular monitoring (including gynaecological examinations, eye checks, and blood tests) is recommended during tamoxifen treatment to detect potential complications early.
How Should You Store Tamoxifen?
Store tamoxifen tablets at room temperature (below 25°C / 77°F), away from light and moisture, out of the reach and sight of children. Do not use after the expiry date printed on the packaging.
Keep the tablets in their original packaging to protect from moisture and light. Store in a dry place at room temperature. Do not store in the bathroom or near a sink. Check the expiry date (marked "EXP" on the carton and blister) before taking any tablets. The expiry date refers to the last day of the stated month.
Do not flush unused tablets down the toilet or throw them in household waste. Because tamoxifen is an anti-cancer medication, it should be disposed of carefully. Return any unused or expired medication to your pharmacy for safe disposal according to local regulations for cytotoxic medicines, which protects both people and the environment.
What Does Tamoxifen Contain?
Each tamoxifen tablet contains the active ingredient tamoxifen (as tamoxifen citrate) and several inactive ingredients necessary for tablet manufacture. The 10 mg tablets are small, round, and white. The 20 mg tablets are similar but slightly larger.
Active Ingredient
The active substance is tamoxifen. Each 10 mg tablet contains tamoxifen citrate equivalent to 10 mg tamoxifen. Each 20 mg tablet contains tamoxifen citrate equivalent to 20 mg tamoxifen. Tamoxifen citrate is the salt form that allows for effective oral absorption.
Inactive Ingredients (Excipients)
Common excipients include: lactose monohydrate, maize starch, sodium starch glycolate, magnesium stearate, methylhydroxypropylcellulose, polyethylene glycol 300, and titanium dioxide. Exact excipients may vary slightly between manufacturers. Check the patient information leaflet for your specific brand.
Lactose Content
Many tamoxifen tablet formulations contain lactose as an excipient. If you have a known lactose intolerance, inform your pharmacist, who may be able to source a lactose-free formulation or advise on managing this.
Tablet Appearance and Packaging
10 mg tablets: White to off-white, round, film-coated tablets.
20 mg tablets: White to off-white, round or oblong, film-coated tablets.
Available in blister packs of 20, 28, 30, 60, 90, and 100 tablets. Not all pack sizes may be marketed in your country. Appearance may vary between manufacturers.
How Does Tamoxifen Work in the Body?
Tamoxifen works by competitively binding to estrogen receptors (ERs) in target tissues. In breast tissue, it blocks estrogen from activating cancer cell growth (anti-estrogenic). In bone, it mimics estrogen's protective effect (pro-estrogenic), helping maintain bone density. In the uterus, its partial estrogenic activity increases the risk of endometrial changes.
Estrogen plays a critical role in the growth and development of estrogen receptor-positive (ER+) breast cancers. When estrogen binds to estrogen receptors on breast cancer cells, it triggers a cascade of signals that promote cell division and tumour growth. Tamoxifen works by competitively occupying the estrogen receptor, preventing estrogen from binding and activating the receptor. This effectively starves ER+ cancer cells of the growth signal they depend on.
What makes tamoxifen unique among anti-estrogen drugs is its tissue-selective activity. In breast tissue, tamoxifen acts as an estrogen antagonist (blocker), inhibiting tumour cell proliferation. However, in other tissues such as bone and the endometrium, tamoxifen acts as a partial estrogen agonist (mimicking estrogen). This tissue-selective behaviour is why tamoxifen is classified as a Selective Estrogen Receptor Modulator (SERM) rather than a pure anti-estrogen.
The beneficial estrogenic effect on bone means that tamoxifen helps preserve bone mineral density, particularly in postmenopausal women who are at risk of osteoporosis. This contrasts with aromatase inhibitors (such as letrozole and anastrozole), which block estrogen production entirely and can accelerate bone loss.
The unwanted estrogenic effect on the uterus means that tamoxifen stimulates the endometrium (uterine lining), which can lead to endometrial thickening, polyps, hyperplasia, and in rare cases, endometrial cancer. This is why regular gynaecological monitoring is essential during treatment.
Pharmacokinetic Profile
Tamoxifen is well absorbed after oral administration, with peak plasma concentrations reached approximately 5 hours after dosing. It is extensively metabolised in the liver, primarily by CYP2D6 and CYP3A4, to form active metabolites. The most important active metabolite is endoxifen, which is approximately 100 times more potent than tamoxifen itself at inhibiting estrogen receptor signalling. Another active metabolite, 4-hydroxytamoxifen, has similar potency but is present at much lower concentrations.
Tamoxifen has a long elimination half-life of 5–7 days, and its active metabolites have half-lives of approximately 14 days. This means that steady-state plasma concentrations are reached after approximately 4 weeks of daily dosing, and the drug remains active for several weeks after discontinuation. Tamoxifen is highly protein-bound (approximately 99%) and is excreted mainly via the faeces.
Frequently Asked Questions About Tamoxifen
The standard treatment duration for tamoxifen in early-stage ER-positive breast cancer is 5 to 10 years. Landmark trials such as the ATLAS and aTTom studies demonstrated that 10 years of tamoxifen further reduces breast cancer recurrence and mortality compared to 5 years. Your oncologist will determine the optimal duration based on your individual risk factors, menopausal status, side effect profile, and whether switching to an aromatase inhibitor is appropriate.
Some patients report modest weight gain while taking tamoxifen, although large clinical studies have produced mixed results on whether tamoxifen itself directly causes significant weight gain. Weight changes during breast cancer treatment may be multifactorial – related to menopausal transition, reduced physical activity, changes in metabolism, or psychological factors rather than the drug alone. Maintaining a healthy balanced diet and regular physical activity can help manage weight during tamoxifen therapy. Discuss any significant or concerning weight changes with your oncologist.
Hot flashes are the most common side effect of tamoxifen, affecting up to 80% of patients. Practical management strategies include: wearing lightweight, layered clothing; keeping rooms cool with fans; avoiding common triggers (spicy food, caffeine, alcohol, hot drinks); exercising regularly; practising relaxation techniques such as deep breathing or mindfulness; and maintaining a healthy weight. If hot flashes are severe and significantly impact your quality of life, your doctor may prescribe venlafaxine or gabapentin, which have shown effectiveness in clinical trials. Crucially, avoid fluoxetine and paroxetine as they reduce tamoxifen's anti-cancer effectiveness by inhibiting CYP2D6.
Tamoxifen is strictly contraindicated during pregnancy because it can cause serious harm to the developing fetus, including birth defects. Although tamoxifen can stimulate ovulation in premenopausal women (potentially increasing fertility), you must use effective non-hormonal contraception (such as condoms, a diaphragm, or a copper IUD) throughout treatment and for at least 2 months after stopping tamoxifen. Hormonal contraceptives (the pill, patches, hormonal IUDs, implants) should be avoided as they may interfere with tamoxifen's action. If you wish to become pregnant in the future, discuss the timing carefully with your oncologist – a temporary treatment pause may be considered in select cases.
CYP2D6 pharmacogenomic testing can identify patients who are poor metabolizers and may not efficiently convert tamoxifen to its active metabolite endoxifen. Approximately 7–10% of Caucasians are CYP2D6 poor metabolizers. The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines recommending consideration of CYP2D6 testing to guide tamoxifen therapy. If you are found to be a poor metabolizer, your oncologist may consider alternative endocrine therapy (such as an aromatase inhibitor with ovarian suppression in premenopausal women). However, CYP2D6 testing is not yet universally mandated. Discuss with your oncologist whether testing is appropriate for your situation.
Yes, tamoxifen is the standard endocrine therapy for male breast cancer. Although male breast cancer is rare (approximately 1% of all breast cancers), about 90% of male breast cancers are estrogen receptor-positive and respond to tamoxifen. ASCO and NCCN guidelines recommend tamoxifen 20 mg daily for 5 years in men with ER-positive early-stage breast cancer. Aromatase inhibitors alone are generally less effective in men because they do not fully suppress estrogen production unless combined with a GnRH agonist. Side effects in men may include hot flashes, decreased libido, erectile dysfunction, and mood changes.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The Lancet. 2011;378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8
- Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2013;381(9869):805–816. doi:10.1016/S0140-6736(12)61963-1
- Burstein HJ, Lacchetti C, Griggs JJ, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. 2019;37(5):423–438. doi:10.1200/JCO.18.01160
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Goetz MP, Sangkuhl K, Guchelaar HJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical Pharmacology & Therapeutics. 2018;103(5):770–777. doi:10.1002/cpt.1007
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 2005;97(22):1652–1662. doi:10.1093/jnci/dji372
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Tamoxifen – Summary of Product Characteristics. EMA product information database. Accessed March 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in oncology, clinical pharmacology, and internal medicine.
Medical Writers
Board-certified physicians specialising in oncology and clinical pharmacology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (ASCO, NCCN, WHO, EMA), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.